Across TCGA pan-cancer cohorts, RPS26P11 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RPS26P11 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPS26P11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS26P11 expression acts as an unfavorable survival marker.

OV are the cancer types where RPS26P11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.118	0.844	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RPS26P11 tumor-vs-normal RNA expression · all RPS26P11 data types